Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Earnings

Cheelcare Announces Third Quarter 2026 Financial Results

Cheelcare Scales Revenue but Cash Burn Threatens Runway as Stock Fades from Peak

By The Northwire Desk — AI Analysis Mar 25, 2026 · 07:31 CHER · 1.72 Cheelcare Inc.
Executive Summary
  • Cheelcare reported Q3 FY2026 financial results with record quarterly revenue of CAD $549,857, representing a 16% year-over-year increase.
  • Gross profit margin expanded to 44.3%, up from 31.2% in the prior year quarter, indicating improved unit economics.
  • Net loss widened to $(509,824) or $(0.02) per share, driven by investments in production scale-up, regulatory compliance, and public-company overhead.
  • Cash and cash equivalents stood at a critically low $83,642 as of January 31, 2026, with working capital at $355,047.
  • The company closed a $1.0 million unsecured promissory note financing on February 18, 2026, to fund working capital, inventory, and manufacturing expansion.
  • Operational updates confirmed PDAC verification for Medicare/Medicaid reimbursement, cumulative sales exceeding 2,000 Companion units, a distribution network surpassing 500 dealer locations, and a Health Canada "Compliant" facility rating.
  • Natasha Tsai was appointed CFO effective April 7, 2026, replacing Arnab De.
Material Impact
  • The revenue growth and margin improvement are constructive but were fully anticipated following the January 2026 PDAC approval and December 2025 sales milestones.
  • The widening net loss and near-zero cash balance represent a severe liquidity constraint that overshadows top-line progress. The company is burning capital faster than it generates revenue.
  • The $1.0 million financing was already disclosed in February, providing no new catalyst or surprise capital injection.
  • The market has already priced in the operational progress, as evidenced by the stock's decline from its $1.98 peak in mid-February to $1.38 by early April.
  • The release confirms execution on known initiatives but introduces no unexpected positive developments. It is a standard quarterly update that highlights both scaling progress and acute financial vulnerability.
CHER · Price
Company Overview
  • Cheelcare develops assistive mobility technology focused on enhancing independence for wheelchair users.
  • Flagship product: Companion power-assist device, a compact unit that attaches to manual wheelchairs to provide electric propulsion while preserving manual functionality.
  • Secondary pipeline: Curio robotic complex rehabilitation wheelchair, currently in pilot production and undergoing regulatory validation.
  • Manufacturing: 16,000 square foot facility in Markham, Ontario, implementing Toyota Production System principles for scalable assembly and quality control.
  • Commercial footprint: Over 500 authorized dealer locations globally, with a strategic push into U.S. Veterans Affairs Medical Centers and complex rehab networks.
Read the original news release →

More from Cheelcare Inc.

Jun 18, 2026 · 07:31

Cheelcare Announces Upsizing of Non-Brokered Private Placement to $3.0 Million

Financings Jun 11, 2026 · 16:31

Small-cap mobility device maker scales commercialization but relies on recurring capital raises to fund cash burn.

Financings May 28, 2026 · 07:31

Cheelcare Secures Canadian IP Moat as Sales Momentum Builds Amidst Dilution Risks

M&A / Property May 11, 2026 · 07:31

Cheelcare extends its booking streak as Companion reimbursement catalyst takes hold, but the Curio regulatory journey and thin balance sheet keep risk elevated.

Production / Operations Apr 09, 2026 · 07:31

Cheelcare launches first Curio robotic wheelchair, turning R&D into revenue

Production / Operations Feb 18, 2026 · 07:31

Cheelcare Closes $1.0 Million Unsecured Note Financing

Financings